Skip to main content
. Author manuscript; available in PMC: 2016 Apr 12.
Published in final edited form as: Bone Marrow Transplant. 2009 Dec 7;45(7):1212–1219. doi: 10.1038/bmt.2009.329

Table 1. Characteristics of stem cell transplant recipients studied.

No. of transplants, n 206
Median age at transplant, yrs (range) 27 (3-60)
Proportion of males (%) 138 (67 %)
Indication for transplant
    Acute Myeloblastic Leukaemia 61 (30 %)
    Acute Lymphoblastic Leukaemia 52 (25 %)
    Chronic Myeloid Leukaemia 30 (15 %)
    Myelodysplastic Syndrome 16 (8 %)
    Non-Hodgkin’s Lymphoma 12 (6 %)
    Other Malignant Disordera 12 (6 %)
    Other Non-malignant Disorderb 23 (11 %)
Risk Group
    Good prognosis 86 (42 %)
    Poor prognosis 120 (58 %)
Donor Type
    Sibling 130 (63 %)
    Non-sibling related donor 8 (4 %)
    Unrelated donor 68 (33 %)
HLA Match c
    6 Antigen match 183 (89 %)
    Less than 6 antigen match 21 (10 %)
Source of Graft d
    Bone marrow 141 (68 %)
    Peripheral blood stem cell 64 (31 %)
Median CD34 dose ×106/kg recipient weighte (range) 2.6 (0.2-18.4)
Type of transplant
    Reduced intensity conditioning 12 (6 %)
    Myeloablative 194 (94 %)
Pre-transplant conditioning
    Non radiotherapy based conditioning 41 (20 %)
    Radiotherapy based conditioning 165 (80 %)
Campath In Vivo Usef
    No Campath in vivo 105 (51 %)
    Campath-IG in vivo 44 (21 %)
    Campath-IH in vivo 52 (25 %)
Form of Ex vivo T-Cell Depletion
    No ex vivo T-Cell Depletion 116 (56 %)
    Campath-IG 43 (21 %)
    Campath-IH 40 (19 %)
    CD34 selection 7 (3 %)
HCMV serology (recipient/donor)g
    Neg/Neg 56 (26 %)
    Neg/Pos 20 (10 %)
    Pos/Neg 36 (17 %)
    Pos/Pos 94 (46 %)
a

Idiopathic myelofibrosis, multiple myeloma, sarcoma,

b

Aplastic anaemia, Fanconi anaemia, thalassaemia major, metachromic leucodystrophy

c

HLA tissue typing data unavailable in 2 recipient/donor pairs

d

source of graft unavailable for 1 patient

e

CD34 dose unavailable in 17 patients

f

In-vivo Campath use data unavailable in 5 patients

g

HCMV serology unavailable in 3 recipient/donor pairs